HLCM051

Healios is a Japanese biotechnology company specializing in the development of regenerative medicine and cell therapies using induced pluripotent stem cell (iPSC) technology. The company's lead pipeline candidate, HLCM051 (MultiStem), is a somatic stem cell product being evaluated for the treatment of acute respiratory distress syndrome (ARDS) and ischemic stroke. Healios is also advancing a proprietary 'Universal Donor iPSC' platform to create next-generation cell therapies that can be administered without the need for HLA matching. Their research extends into immuno-oncology, specifically developing iPSC-derived natural killer (NK) cells for solid tumors, and regenerative treatments for ophthalmology and organ repair.